Syqe Medical

Company Overview

Snapshot

Founded in March 2011 by Perry Davidson, Syqe Medical operates with 51–200 employees. The company has raised $72.65 million across 3 funding rounds from 7 investors. In November 2023, its SyqeAir Inhaler obtained ARTG Approval in Australia, marking a significant milestone in medicinal cannabis treatment.

Business overview

Syqe Medical is a MedTech company specializing in a breakthrough technology for medical cannabis administration. Its core product, the SyqeAir Inhaler, is a unique platform designed to enable physicians and patients to manage cannabis treatment safely and effectively. The device ensures metered dosing, lowest effective dose, and safety of use, delivering a consistent and personalized amount of THC from raw medical cannabis inflorescence with each inhalation. The company serves the healthcare industry, focusing on patients seeking pain reduction and improved sleep quality, operating within the Health Tech & Life Sciences sector, specifically Medical Cannabis and Medical Devices.

Strategic signal

In July 2025, Syqe Medical announced structural adjustments, primarily in its development department, including job cuts. This move is aimed at focusing resources on securing US FDA clearance, following a 2023 deal to be acquired by Philip Morris pending this approval. This indicates a strategic pivot towards regulatory approval in a key market, signaling a critical phase in the company's trajectory and potential for future market expansion.

Company Intelligence Q&A

What is the primary product developed by Syqe Medical?

Syqe Medical developed the SyqeAir Inhaler, a programmable drug-delivery inhalation platform for medical cannabis, designed to provide consistent and metered doses of THC from raw medical cannabis inflorescence.

What significant regulatory approval did Syqe Medical receive in late 2023?

In November 2023, Syqe Medical's SyqeAir Inhaler obtained ARTG Approval in Australia, which was a historic milestone for medicinal cannabis treatment in the region.

What strategic move did Syqe Medical make in July 2025 regarding its workforce?

In July 2025, Syqe Medical implemented structural adjustments, including layoffs, primarily within its development department. This decision was made to concentrate resources on securing FDA approval in the United States.

Which company is reportedly acquiring Syqe Medical?

In July 2023, Philip Morris was reported to be acquiring Cannabis inhaler developer Syqe Medical for up to $650 million, pending FDA approval.

When did Syqe Medical enter into a distribution agreement with TerrAscend for the Canadian market?

In September 2019, Syqe Medical entered into a distribution agreement with TerrAscend to bring its medical cannabis treatment to Canada.